Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viridian TherapeuticsVRDN -1.11%49 Cash-to-Debt is 4.04 as of Jun. 2026, which is 75% below its 10-year median of 16.14. GuruFocus rates VRDN with a GF Score™ of 49/100. The stock has 6 warning signs investors should review. Among 1,343 Biotechnology companies, Viridian Therapeutics ranks worse than 58.38% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Viridian Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.04.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Viridian Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Viridian Therapeutics's Cash-to-Debt or its related term are showing as below:
VRDN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.2 Med: 16.14 Max: 497.24
Current: 4.04
During the past 13 years, Viridian Therapeutics's highest Cash to Debt Ratio was 497.24. The lowest was 3.20. And the median was 16.14.
VRDN's Cash-to-Debt is ranked worse than 58.38% of 1343
companies
in the Biotechnology industry
Industry Median: 7.25
vs VRDN: 4.04
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Viridian Therapeutics Cash-to-Debt Related Terms
Viridian Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Viridian Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (VRDN) has a Cash-to-Debt of 4.04 as of Jun. 2026. This is 75% below median its historical median of 16.14. Over the past decade, Viridian Therapeutics' Cash-to-Debt has ranged from 3.20 to 497.24. According to the industry distribution chart, Viridian Therapeutics ranks #784 out of 1343 companies in the Biotechnology industry, placing it in the top 58.4%.
Is Viridian Therapeutics' Cash-to-Debt too high?
Viridian Therapeutics' current Cash-to-Debt of 4.04 is 75% below median its 10-year median of 16.14. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 497.24. The Biotechnology industry median Cash-to-Debt is 7.25. Viridian Therapeutics' value of 4.04 is 44.3% below this industry median. Based on the distribution chart, Viridian Therapeutics ranks #784 out of 1343 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Cash-to-Debt compare to BHVN and AGIO?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #784 out of 1343 companies for Cash-to-Debt. This places Viridian Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 7.25. Viridian Therapeutics' value of 4.04 is 44.3% below this benchmark. Historically, Viridian Therapeutics' own Cash-to-Debt has ranged from 3.20 to 497.24 over the past decade. While the company's 10-year median is 16.14 vs. the industry median of 7.25, Viridian Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viridian Therapeutics's current Cash-to-Debt of 4.04 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viridian Therapeutics's current Cash-to-Debt is 4.04, which is 75% below median its own 10-year median of 16.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (VRDN) has a current Cash-to-Debt of 4.04. The current Cash-to-Debt is 4.04, which is 75% below median its 10-year median of 16.14 and 44.3% below the Biotechnology industry median of 7.25. Viridian Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Viridian Therapeutics (VRDN), the current Cash-to-Debt is 4.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score
Get the complete analysis for VRDN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRDN has been successfully added to your 
